Key facts
- UpFront’s last known valuation is $36.5M (May 2025).
- It has raised $7.1M.
- Notable investors include Innovate UK, Accelerate Cambridge, APEX Ventures, Creator Fund, PanaceaStars — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for UpFront
- ·The full record, as it builds
Funding rounds
No funding rounds for UpFront are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About UpFront
Developer of rapid diagnostic tests designed for stroke identification. The company uses blood biomarkers to detect large vessel occlusion strokes within minutes with high accuracy and single-drop blood tests to identify large vessel occlusion (LVO) strokes in emergency settings, enabling emergency medical professionals, clinicians, paramedics, and nurses to deliver faster and more accurate diagnoses, improving patient outcomes, and reducing healthcare costs.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2017
- Employees
- 8
- Website
- upfrontdiagnostics.com/
- Ownership
- Privately Held (backing)
UpFront doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in UpFront shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on UpFront in its N-PORT filings yet. We sweep new filings monthly.